Equities Analysts Set Expectations for AxoGen Inc.’s FY2016 Earnings (AXGN)
AxoGen Inc. (NASDAQ:AXGN) – Investment analysts at Wedbush raised their FY2016 earnings estimates for shares of AxoGen in a report released on Monday. Wedbush analyst Levy. T now anticipates that the firm will earn ($0.39) per share for the year, up from their prior forecast of ($0.46). Wedbush has a “Outperform” rating and a $12.00 price target on the stock. Wedbush also issued estimates for AxoGen’s Q4 2016 earnings at ($0.10) EPS, FY2017 earnings at ($0.27) EPS, FY2018 earnings at ($0.06) EPS and FY2019 earnings at $0.13 EPS.
Separately, Lake Street Capital cut AxoGen from a “buy” rating to a “hold” rating and set a $9.00 price target for the company. in a research report on Thursday, November 3rd.
Shares of AxoGen (NASDAQ:AXGN) opened at 8.20 on Wednesday. The stock’s 50 day moving average price is $8.70 and its 200 day moving average price is $7.43. AxoGen has a 52-week low of $4.52 and a 52-week high of $9.88. The company’s market capitalization is $269.76 million.
AxoGen (NASDAQ:AXGN) last released its earnings results on Wednesday, November 2nd. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). AxoGen had a negative return on equity of 292.94% and a negative net margin of 33.02%.
A number of hedge funds have recently modified their holdings of AXGN. UBS Group AG boosted its stake in shares of AxoGen by 991.7% in the first quarter. UBS Group AG now owns 97,946 shares of the company’s stock valued at $525,000 after buying an additional 88,974 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of AxoGen by 196.8% in the second quarter. Bank of New York Mellon Corp now owns 80,580 shares of the company’s stock valued at $555,000 after buying an additional 53,427 shares during the last quarter. California State Teachers Retirement System acquired a new position in AxoGen during the second quarter worth $348,000. Nationwide Fund Advisors acquired a new position in AxoGen during the second quarter worth $105,000. Finally, Vanguard Group Inc. boosted its position in AxoGen by 61.5% in the second quarter. Vanguard Group Inc. now owns 775,448 shares of the company’s stock worth $5,335,000 after buying an additional 295,294 shares in the last quarter. Institutional investors own 53.00% of the company’s stock.
In related news, Director Amy Mcbride Wendell bought 13,333 shares of the company’s stock in a transaction on Friday, October 7th. The stock was bought at an average cost of $7.50 per share, for a total transaction of $99,997.50. Following the acquisition, the director now directly owns 13,333 shares in the company, valued at $99,997.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John P. Engels bought 4,000 shares of the company’s stock in a transaction on Friday, October 7th. The stock was bought at an average price of $7.50 per share, with a total value of $30,000.00. Following the completion of the acquisition, the vice president now owns 98,425 shares in the company, valued at $738,187.50. The disclosure for this purchase can be found here. Corporate insiders own 9.33% of the company’s stock.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.